FORBES-TATE

Lobbying for CSL BEHRING · Biopharmaceutical Company

Filing 3rd Quarter - Termination

3rd Quarter (July 1 - Sep 30) 2025 · Pennsylvania · House · Senate · $60,000.00 income · posted Oct 10, 2025

Lobbying activity 2

Medical/Disease Research/Clinical Labs

Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies; Issues related to the Preserving Life-saving Access to Specialty Medicines in America Act.

Medicare/Medicaid

Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.